Overview

Trial of Peg-interferon Plus Epoetin-alfa for Treatment of Chronic Hepatitis C Virus Infection

Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the use of epoetin-alpha will allow patients with chronic hepatitis C virus infection to be treated with higher doses of peginterferon-alpha-2b and ribavirin, thus increasing chances at lower viral levels and raising sustained virologic response.
Phase:
Phase 3
Details
Lead Sponsor:
Virginia Commonwealth University
Collaborator:
Ortho Biotech, Inc.
Treatments:
Epoetin Alfa
Interferon-alpha
Interferons
Peginterferon alfa-2b
Ribavirin